Jenny Chang

发表

ABT-869 a Multi-Targeted Receptor Tyrosine Kinase Inhibitor: Inhibition of FLT3 Phosphorylation and Signaling in Acute Myeloid Leukemia Running Title: ABT-869 Receptor Tyrosine Kinase Inhibitor in AML

K. Glaser, S. Davidsen, Eric F. Johnson, 2007 .

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.

Yujia Dai, K. Glaser, S. Davidsen, 2007, Blood.

CREB is a critical regulator of normal hematopoiesis and leukemogenesis.

K. Sakamoto, D. Shankar, Jerry Cheng, 2008, Blood.

leukemogenesis CREB is a critical regulator of normal hematopoiesis and

D. Shankar, Jerry Cheng, R. Stripecke, 2008 .

AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes.

S. Armstrong, J. Bradner, R. Roeder, 2014, Cancer cell.

Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.

S. Armstrong, E. Olhava, A. Sinha, 2013, Blood.

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

William Pao, Rebecca S. Cook, Carlos L. Arteaga, 2011, Proceedings of the National Academy of Sciences.

The Multi-Targeted Receptor Tyrosine Kinase Inhibitor, ABT-869, Induces Apoptosis of AML Cells Both In Vitro and In Vivo.

K. Glaser, S. Davidsen, K. Sakamoto, 2005 .

CREB is a critical regulator of normal hematopoiesis and leukemogenesis.

K. Sakamoto, D. Shankar, Jerry Cheng, 2008, Blood.

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.

K. Glaser, S. Davidsen, Eric F. Johnson, 2007, Blood.

ABT-869 a Multi-Targeted Receptor Tyrosine Kinase Inhibitor: Inhibition of FLT3 Phosphorylation and Signaling in Acute Myeloid Leukemia Running Title: ABT-869 Receptor Tyrosine Kinase Inhibitor in AML

K. Glaser, S. Davidsen, Eric F. Johnson, 2007 .